| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| NAGENiagen Bioscience Inc | 503.58M | 6.31 | 57.36 | 19.18% | 16.38% | 28.91% | 2.37% | 0.06 |
| BTXBlackRock Technology and Private Equity Term Trust | 808.8M | 6.93 | 40.76 | -81.13% | 87.75% | 1.87% | 34.27% | |
| HALOHalozyme Therapeutics, Inc. | 8.45B | 71.82 | 20.94 | 22.44% | 47.91% | 118.17% | 5.55% | 4.14 |
| RPRXRoyalty Pharma plc | 16.97B | 39.72 | 20.80 | -3.86% | 32.55% | 7.95% | 16.32% | 0.74 |
| REGNRegeneron Pharmaceuticals, Inc. | 76.63B | 741.92 | 19.35 | 8.27% | 32.13% | 14.79% | 4.78% | 0.09 |
| GMABGenmab A/S | 20.85B | 33.85 | 2.79 | 30.67% | 46.8% | 114.25% | 36.37% | 0.03 |
| DNAGinkgo Bioworks Holdings, Inc. | 464.86M | 9.58 | -0.91 | -9.71% | -188% | -60.66% | 0.65 | |
| PRMEPrime Medicine, Inc. | 720.24M | 3.99 | -2.42 | -33.02% | -121.95% | 0.27 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Sales/Revenue | 1.71M | 3.41M | 10M | 39.68M | 43.88M | 58.84M |
| Revenue Growth % | - | 0.99% | 1.93% | 2.97% | 0.11% | 0.34% |
| Cost of Goods Sold | 45.81M | 0 | 0 | 48.27M | 42.59M | 45.24M |
| COGS % of Revenue | 26.77% | - | - | 1.22% | 0.97% | 0.77% |
| Gross Profit | -44.1M | 3.41M | 10M | -8.59M | 1.29M | 13.6M |
| Gross Margin % | -25.77% | 1% | 1% | -0.22% | 0.03% | 0.23% |
| Gross Profit Growth % | - | 1.08% | 1.93% | -1.86% | 1.15% | 9.55% |
| Operating Expenses | 64.15M | 88.03M | 192.78M | 237.13M | 351.35M | 492.61M |
| OpEx % of Revenue | 37.49% | 25.79% | 19.28% | 5.98% | 8.01% | 8.37% |
| Selling, General & Admin | 18.95M | 25.26M | 57.68M | 81.6M | 110.82M | 178.18M |
| SG&A % of Revenue | 11.08% | 7.4% | 5.77% | 2.06% | 2.53% | 3.03% |
| Research & Development | 45.81M | 63.32M | 135.27M | 155.7M | 241.23M | 314.42M |
| R&D % of Revenue | 26.77% | 18.55% | 13.53% | 3.92% | 5.5% | 5.34% |
| Other Operating Expenses | -608K | -549K | -178K | -162K | -699K | 0 |
| Operating Income | -62.44M | -84.61M | -182.78M | -245.73M | -350.06M | -479M |
| Operating Margin % | -36.49% | -24.79% | -18.28% | -6.19% | -7.98% | -8.14% |
| Operating Income Growth % | - | -0.36% | -1.16% | -0.34% | -0.42% | -0.37% |
| EBITDA | -58.9M | -80.67M | -174.37M | -233.97M | -325.66M | -442.51M |
| EBITDA Margin % | -34.42% | -23.64% | -17.44% | -5.9% | -7.42% | -7.52% |
| EBITDA Growth % | - | -0.37% | -1.16% | -0.34% | -0.39% | -0.36% |
| D&A (Non-Cash Add-back) | 3.54M | 3.94M | 8.4M | 11.76M | 24.4M | 36.49M |
| EBIT | -61.88M | -85.65M | -183.53M | -239.42M | -332.03M | -463.22M |
| Net Interest Income | 1.11M | -1.02M | -2.88M | 6.2M | 19.02M | 14.19M |
| Interest Income | 1.74M | 336K | 73K | 6.25M | 19.12M | 15.76M |
| Interest Expense | 635K | 1.36M | 2.95M | 55K | 97K | 1.57M |
| Other Income/Expense | 562K | -2.39M | -3.7M | 6.25M | 17.93M | 14.22M |
| Pretax Income | -61.88M | -87.01M | -186.48M | -239.48M | -332.13M | -464.79M |
| Pretax Margin % | -36.17% | -25.49% | -18.65% | -6.04% | -7.57% | -7.9% |
| Income Tax | 0 | 0 | 0 | 0 | -4.06M | -1.13M |
| Effective Tax Rate % | 1.01% | 1% | 1% | 1% | 0.99% | 1% |
| Net Income | -62.52M | -87.01M | -186.48M | -239.48M | -328.07M | -463.66M |
| Net Margin % | -36.54% | -25.49% | -18.65% | -6.04% | -7.48% | -7.88% |
| Net Income Growth % | - | -0.39% | -1.14% | -0.28% | -0.37% | -0.41% |
| Net Income (Continuing) | -61.88M | -87.01M | -186.48M | -239.48M | -328.07M | -463.66M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.37 | -0.52 | -1.05 | -1.36 | -1.58 | -1.69 |
| EPS Growth % | - | -0.41% | -1% | -0.3% | -0.16% | -0.07% |
| EPS (Basic) | -0.37 | -0.52 | -1.05 | -1.36 | -1.58 | -1.69 |
| Diluted Shares Outstanding | 165.79M | 165.79M | 170.27M | 175.54M | 207.85M | 274.21M |
| Basic Shares Outstanding | 165.79M | 165.79M | 170.27M | 175.54M | 207.85M | 274.21M |
| Dividend Payout Ratio | - | - | - | - | - | - |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 76.4M | 266.44M | 534.72M | 569.81M | 438.14M | 714.27M |
| Cash & Short-Term Investments | 69.88M | 262.13M | 516.56M | 549.91M | 391.56M | 594.35M |
| Cash Only | 69.88M | 262.13M | 285.12M | 549.91M | 391.56M | 594.35M |
| Short-Term Investments | 0 | 0 | 231.45M | 0 | 0 | 0 |
| Accounts Receivable | 151K | 156K | 9.09M | 2.75M | 3.09M | 49.17M |
| Days Sales Outstanding | 32.21 | 16.68 | 331.79 | 25.32 | 25.74 | 304.99 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - |
| Other Current Assets | 6.36M | 4.16M | 9.07M | 17.15M | 43.48M | 70.75M |
| Total Non-Current Assets | 25.03M | 32.15M | 75.63M | 131.47M | 215.56M | 734.33M |
| Property, Plant & Equipment | 24.37M | 25.97M | 64.72M | 121.45M | 120.17M | 233.21M |
| Fixed Asset Turnover | 0.07x | 0.13x | 0.15x | 0.33x | 0.37x | 0.25x |
| Goodwill | 0 | 801K | 801K | 801K | 52.06M | 148.87M |
| Intangible Assets | 0 | 1.69M | 1.39M | 1.31M | 36.44M | 335.86M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 5.63M |
| Other Non-Current Assets | 663K | 3.69M | 8.72M | 7.92M | 6.89M | 8.82M |
| Total Assets | 101.43M | 298.58M | 610.35M | 701.29M | 653.7M | 1.45B |
| Asset Turnover | 0.02x | 0.01x | 0.02x | 0.06x | 0.07x | 0.04x |
| Asset Growth % | - | 1.94% | 1.04% | 0.15% | -0.07% | 1.22% |
| Total Current Liabilities | 6.68M | 23.1M | 46.66M | 100.27M | 93.17M | 187.47M |
| Accounts Payable | 1.26M | 1.07M | 2.82M | 4.59M | 3.95M | 21.61M |
| Days Payables Outstanding | 10.05 | - | - | 34.67 | 33.88 | 174.38 |
| Short-Term Debt | 77K | 1.07M | 90K | 97K | 41K | 22.22M |
| Deferred Revenue (Current) | 0 | 1000K | 1000K | 1000K | 1000K | 1000K |
| Other Current Liabilities | 1.7M | 3.08M | 11.74M | 20.43M | 23.75M | 81.87M |
| Current Ratio | 11.43x | 11.53x | 11.46x | 5.68x | 4.70x | 3.81x |
| Quick Ratio | 11.43x | 11.53x | 11.46x | 5.68x | 4.70x | 3.81x |
| Cash Conversion Cycle | - | - | - | - | - | - |
| Total Non-Current Liabilities | 219.01M | 481.77M | 20.75M | 115.22M | 97.09M | 226.34M |
| Long-Term Debt | 12.42M | 11.41M | 633K | 536K | 1.1M | 19.02M |
| Capital Lease Obligations | 3.21M | 2.71M | 9.34M | 44.42M | 43.41M | 67.25M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 1.34M | 16.57M |
| Other Non-Current Liabilities | 203.39M | 450.99M | 4.11M | 0 | 0 | 4.73M |
| Total Liabilities | 225.7M | 504.87M | 67.41M | 215.48M | 190.26M | 413.82M |
| Total Debt | 16.17M | 15.66M | 11.48M | 51.01M | 50.67M | 108.49M |
| Net Debt | -53.71M | -246.46M | -273.64M | -498.91M | -340.89M | -485.86M |
| Debt / Equity | - | - | 0.02x | 0.10x | 0.11x | 0.10x |
| Debt / EBITDA | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - |
| Interest Coverage | -98.33x | -62.22x | -61.92x | -4467.76x | -3608.87x | -304.71x |
| Total Equity | -124.27M | -206.29M | 542.94M | 485.81M | 463.44M | 1.03B |
| Equity Growth % | - | -0.66% | 3.63% | -0.11% | -0.05% | 1.23% |
| Book Value per Share | -0.75 | -1.24 | 3.19 | 2.77 | 2.23 | 3.77 |
| Total Shareholders' Equity | -124.27M | -206.29M | 542.94M | 485.81M | 463.44M | 1.03B |
| Common Stock | 0 | 0 | 2K | 2K | 2K | 4K |
| Retained Earnings | -126.59M | -213.6M | -400.08M | -639.56M | -967.62M | -1.43B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | -126K | 0 | 0 | -7.64M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Cash from Operations | -57.04M | -45.4M | -158.61M | -83.52M | -287.78M | -359.17M |
| Operating CF Margin % | -33.34% | -13.3% | -15.86% | -2.1% | -6.56% | -6.1% |
| Operating CF Growth % | - | 0.2% | -2.49% | 0.47% | -2.45% | -0.25% |
| Net Income | -61.88M | -87.01M | -186.48M | -239.48M | -328.07M | -463.66M |
| Depreciation & Amortization | 2.49M | 3.94M | 8.4M | 11.76M | 24.4M | 36.49M |
| Stock-Based Compensation | 1.39M | 4.29M | 14.84M | 27.91M | 53.5M | 81.69M |
| Deferred Taxes | 0 | 0 | 827K | 0 | 0 | 0 |
| Other Non-Cash Items | 555K | 2.54M | 4.1M | 11.37M | 12.64M | 24.31M |
| Working Capital Changes | 408K | 30.83M | -306K | 104.92M | -50.26M | -38M |
| Change in Receivables | 605K | -1.12M | 114K | -2K | 0 | -6.07M |
| Change in Inventory | 0 | 0 | 7.83M | 0 | 0 | 0 |
| Change in Payables | -340K | -185K | 1.75M | 1.77M | -987K | 6.43M |
| Cash from Investing | -3.91M | -8.74M | -271.74M | 193.25M | -10.23M | 260.06M |
| Capital Expenditures | -3.91M | -5.83M | -39.8M | -37.06M | -11.96M | -13.7M |
| CapEx % of Revenue | 2.29% | 1.71% | 3.98% | 0.93% | 0.27% | 0.23% |
| Acquisitions | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | -309K | -231.95M | -300K | -597K | -3.35M |
| Cash from Financing | 120.41M | 246.13M | 458.54M | 154.34M | 140.13M | 304.12M |
| Debt Issued (Net) | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - |
| Other Financing | -210K | 681K | 8.44M | 10.72M | 12.81M | 8.14M |
| Net Change in Cash | - | - | - | - | - | - |
| Free Cash Flow | -60.95M | -52.13M | -198.41M | -120.88M | -300.33M | -372.87M |
| FCF Margin % | -35.62% | -15.28% | -19.84% | -3.05% | -6.85% | -6.34% |
| FCF Growth % | - | 0.14% | -2.81% | 0.39% | -1.48% | -0.24% |
| FCF per Share | -0.37 | -0.31 | -1.17 | -0.69 | -1.44 | -1.36 |
| FCF Conversion (FCF/Net Income) | 0.91x | 0.52x | 0.85x | 0.35x | 0.88x | 0.77x |
| Interest Paid | 485K | 989K | 0 | 55K | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -110.79% | -46.56% | -69.12% | -61.9% |
| Return on Invested Capital (ROIC) | - | - | - | -143.87% | -479.79% | -107.01% |
| Gross Margin | -2577.32% | 100% | 100% | -21.66% | 2.94% | 23.12% |
| Net Margin | -3654.3% | -2549.25% | -1864.79% | -603.5% | -747.71% | -788.02% |
| Debt / Equity | - | - | 0.02x | 0.10x | 0.11x | 0.10x |
| Interest Coverage | -98.33x | -62.22x | -61.92x | -4467.76x | -3608.87x | -304.71x |
| FCF Conversion | 0.91x | 0.52x | 0.85x | 0.35x | 0.88x | 0.77x |
| Revenue Growth | - | 99.47% | 193% | 296.81% | 10.57% | 34.1% |
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| License and Service | 10M | 39.68M | 43.88M | 58.49M |
| License and Service Growth | - | 296.81% | 10.57% | 33.30% |
| Grant | 178K | 162K | 699K | 351K |
| Grant Growth | - | -8.99% | 331.48% | -49.79% |
Recursion Pharmaceuticals, Inc. (RXRX) reported $43.5M in revenue for fiscal year 2024. This represents a 2444% increase from $1.7M in 2019.
Recursion Pharmaceuticals, Inc. (RXRX) grew revenue by 34.1% over the past year. This is strong growth.
Recursion Pharmaceuticals, Inc. (RXRX) reported a net loss of $715.5M for fiscal year 2024.
Recursion Pharmaceuticals, Inc. (RXRX) has a return on equity (ROE) of -61.9%. Negative ROE indicates the company is unprofitable.
Recursion Pharmaceuticals, Inc. (RXRX) had negative free cash flow of $448.0M in fiscal year 2024, likely due to heavy capital investments.